Evidence map›Paper›PMID 33563817›Full record

SynthesismBio2021

Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis.

Wern Hann Ng, Thomas Tipih, Nigel A Makoah, Jan-G Vermeulen, Dominique Goedhals, Joseph B Sempa, Felicity J Burt, Adam Taylor, Suresh Mahalingam

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed, 7 pooled it
18.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

173 citing papers in PubMed, 7 syntheses or guidelines pooled it, 299 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article

113 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Wern Hann Ng *Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University, Gold Coast, Southport, QLD, Australia.ORCID 0000-0001-8438-7203
Thomas Tipih *Division of Virology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.ORCID 0000-0003-3845-1942
Nigel A MakoahDivision of Virology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.ORCID 0000-0002-1396-6205
Jan-G VermeulenDivision of Virology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.ORCID 0000-0003-4269-7195
Dominique GoedhalsDivision of Virology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.ORCID 0000-0002-1241-9111
Joseph B SempaDepartment of Biostatistics, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.ORCID 0000-0003-1062-0417
Felicity J Burt *Division of Virology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa BurtFJ@ufs.ac.za s.mahalingam@griffith.edu.au.ORCID 0000-0002-7238-7799
Adam Taylor *Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University, Gold Coast, Southport, QLD, Australia.ORCID 0000-0002-7159-3961
Suresh Mahalingam *Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University, Gold Coast, Southport, QLD, Australia BurtFJ@ufs.ac.za s.mahalingam@griffith.edu.au.ORCID 0000-0003-3141-8410
Griffith University · AUUniversity of the Free State · ZANational Health Laboratory Service · ZAStellenbosch University · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread across the globe at unprecedented speed and is showing no signs of slowing down. The outbreak of coronavirus disease 2019 (COVID-19) has led to significant health burden in infected patients especially in those with underlying comorbidities. The aim of this study was to evaluate the correlation between comorbidities and their role in the exacerbation of disease in COVID-19 patients leading to fatal outcomes. A systematic review was conducted using data from MEDLINE, Scopus, Web of Science, and EMBASE databases published from 1 December 2019 to 15 September 2020. Fifty-three articles were included in the systematic review. Of those 53 articles, 8 articles were eligible for meta-analysis. Hypertension, obesity, and diabetes mellitus were identified to be the most prevalent comorbidities in COVID-19 patients. Our meta-analysis showed that cancer, chronic kidney diseases, diabetes mellitus, and hypertension were independently associated with mortality in COVID-19 patients. Chronic kidney disease was statistically the most prominent comorbidity leading to death. However, despite having high prevalence, obesity was not associated with mortality in COVID-19 patients.

Indexed as

SARS-CoV-2ComorbidityCOVID-19HospitalizationHumansPrevalenceRisk FactorsTreatment OutcomecomorbidityCOVID-19SARS-CoV-2

Identifiers

PMID33563817
PMCPMC7885108
OpenAlexW3127240052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.